Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension

NCT06441630 is registered in ClinicalTrials.gov with Addpharma Inc. as lead sponsor.

NCT NCT06441630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
Lead sponsor
Addpharma Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 31, 2024
Completion date
September 30, 2025
Enrollment
251 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension